Figure 3.
Kaplan-Meier graphs demonstrating the percentage of patients predicted to achieve 2-log reduction by 3 months and 3-log reduction by 12 months. These graphs are based on (A) overall IC50imatinib, (B) Sokal score, (C) patients within the low Sokal group only, and (D) patients with a high Sokal score only.